Who are the top shareholders of the Roselabs Finance?

The top shareholder of Roselabs Finance is Macrotech Developers Limited, holding 74.25% of the shares. Other significant shareholders include Arhanathji Builders And Farms Pvt Ltd at 4.96% and individual investors with a collective 15.15%.

The top shareholders of Roselabs Finance are primarily the promoters, with Macrotech Developers Limited holding the largest share at 74.25%. There are no pledged promoter holdings, and currently, there are no mutual funds or foreign institutional investors involved. The highest public shareholder is Arhanathji Builders And Farms Pvt Ltd, which holds 4.96%. Additionally, individual investors collectively hold 15.15% of the shares.

What does Roselabs Finance do?

Roselabs Finance Ltd is a Micro Cap NBFC established in 1995, primarily involved in non-banking finance. As of March 2025, it reported net sales of 1 Cr and a market cap of Rs 32 Cr.

Overview: <BR>Roselabs Finance Ltd operates in the Non-Banking Financial Company (NBFC) sector and is categorized as a Micro Cap company.<BR><BR>History: <BR>Incorporated on 4th January, 1995, Roselabs Finance initially engaged in Non-Banking Finance. In 2012-13, it became a direct subsidiary of Arihant Premises Private Limited and a step down subsidiary of Lodha Developers Private Limited as of 10th June, 2013. The most recent quarterly results report net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 32 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 23 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -1.04 <BR>Return on Equity: 6.13% <BR>Price to Book: -6.81<BR><BR>Contact Details: <BR>Address: 412 4th Flr 17G Vardhaman Cham, Cawasji Patel Road Fort Mumbai Maharashtra : 400001 <BR>Email: roselabsfinance@lodhagroup.com <BR>Website: http://www.roselabsfinancelimited.in

Who are in the management team of Roselabs Finance?

As of March 2023, the management team of Roselabs Finance includes Chairperson Sanjyot Rangnekar, Non-Executive Directors Prakash Lavji Vaghela and Mayank Padiya, Company Secretary Abhijeet Shinde, and Managing Director Raghava Reddy Balineni. Each member plays a key role in the company's governance and operations.

As of March 2023, the management team of Roselabs Finance includes the following individuals:<BR><BR>1. Sanjyot Rangnekar - Chairperson<BR>2. Prakash Lavji Vaghela - Non-Executive & Independent Director<BR>3. Mayank Padiya - Non-Executive & Independent Director<BR>4. Abhijeet Shinde - Company Secretary & Compliance Officer<BR>5. Raghava Reddy Balineni - Managing Director<BR><BR>Each member holds a distinct role within the company, contributing to its governance and operations.

Has Roselabs Finance declared dividend?

No Dividend History Available

Who are the peers of the Roselabs Finance?

Peers of Roselabs Finance include Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Vertex Secur., Viji Finance, Abhishek Finle., and India Cem. Cap. Management risk varies from excellent to below average among these peers, with Abhishek Finle. showing the highest 1-year return at 88.72% and Jio Financial the lowest at -20.19%.

Peers: The peers of Roselabs Finance are Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Vertex Secur., Viji Finance, Abhishek Finle., and India Cem. Cap.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bajaj Finance, Cholaman.Inv.&Fn, and Muthoot Finance, while Average management risk is found at Jio Financial, and Good management risk is noted at Shriram Finance. Below Average management risk is present at Vertex Secur., Viji Finance, Abhishek Finle., and India Cem. Cap. Growth is Excellent at Jio Financial, Good at Bajaj Finance and Cholaman.Inv.&Fn, and Average at Muthoot Finance and Shriram Finance, while Roselabs Finance does not qualify. Below Average growth is seen at Vertex Secur., Viji Finance, Abhishek Finle., and India Cem. Cap. Capital Structure is Excellent at Bajaj Finance, Jio Financial, Shriram Finance, Muthoot Finance, Vertex Secur., and India Cem. Cap., while Good is seen at Cholaman.Inv.&Fn, and the rest do not qualify.<BR><BR>Return Snapshot: Abhishek Finle. has the highest 1-year return at 88.72%, while Jio Financial has the lowest at -20.19%. Roselabs Finance's 1-year return is -0.16%, which is higher than Jio Financial's but lower than Abhishek Finle.'s. Additionally, the six-month returns are negative for Vertex Secur., Viji Finance, and India Cem. Cap.

What is the technical trend for Roselabs Finance?

As of June 4, 2025, Roselabs Finance shows a mildly bearish trend overall, influenced by daily moving averages and a monthly MACD, despite mixed signals from the weekly MACD and other indicators.

As of 4 June 2025, the technical trend for Roselabs Finance has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish, suggesting mixed signals across time frames. The daily moving averages are mildly bearish, reinforcing the current bearish trend. The Bollinger Bands show a sideways movement on the weekly chart but are mildly bullish on the monthly chart, indicating potential volatility. The KST and OBV are both mildly bullish on the weekly, but the monthly KST is mildly bearish, which adds to the uncertainty. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly MACD.

When is the next results date for Roselabs Finance?

The next results date for Roselabs Finance is 18 July 2025.

The next results date for Roselabs Finance is scheduled for 18 July 2025.

How big is Roselabs Finance?

As of 24th July, Roselabs Finance Ltd has a market capitalization of 27.00 Cr and reported Net Sales of 0.71 Cr with a Net Profit loss of 0.30 Cr over the latest four quarters. As of March 2025, Shareholder's Funds were at a loss of 4.73 Cr, with Total Assets of 0.12 Cr.

As of 24th July, Roselabs Finance Ltd has a market capitalization of 27.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Roselabs Finance reported Net Sales of 0.71 Cr. However, the company experienced a loss of 0.30 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025. At that time, Shareholder's Funds were reported at a loss of 4.73 Cr, while Total Assets stood at 0.12 Cr.

Are Roselabs Finance latest results good or bad?

Roselabs Finance's latest results are concerning, showing a net loss of ₹0.06 crores in Q2 FY26, no revenue, and a negative book value per share of -₹4.73, indicating significant financial struggles and caution for investors.

The latest results for Roselabs Finance indicate a concerning financial situation. In Q2 FY26, the company reported a net loss of ₹0.06 crores, which is a 20% increase in losses compared to the previous quarter. Notably, the company generated no revenue during this period, continuing a trend of sporadic revenue generation over the last several quarters.<BR><BR>Additionally, Roselabs Finance has a negative book value per share of -₹4.73, reflecting a complete erosion of equity due to accumulated losses. The total debt stands at ₹4.93 crores, but with no revenue-generating assets, this raises significant concerns about the company's financial health and sustainability.<BR><BR>Overall, the combination of consistent losses, zero revenue, negative net worth, and a lack of operational infrastructure paints a bleak picture for Roselabs Finance. Investors should approach the company with extreme caution, as it appears to be struggling significantly in a competitive financial landscape.

Should I buy, sell or hold Roselabs Finance?

How has been the historical performance of Roselabs Finance?

Roselabs Finance has experienced a gradual increase in net sales, reaching 0.71 Cr in March 2025, but reported losses in operating profit, profit before tax, and profit after tax of -0.29 Cr. The company faces ongoing financial challenges, with negative reserves and stagnant cash flow.

Answer:<BR>The historical performance of Roselabs Finance shows a gradual increase in net sales, reaching 0.71 Cr in March 2025, up from 1.14 Cr in March 2024, and starting from zero in the previous years. The total operating income followed a similar trend, with a peak of 1.14 Cr in March 2024 and a slight decline in March 2025. The company has consistently reported no raw material costs or purchases of finished goods, indicating minimal operational activity. Employee costs have increased slightly from 0.05 Cr in March 2024 to 0.06 Cr in March 2025. Manufacturing expenses peaked at 1.13 Cr in March 2024 but decreased to 0.70 Cr in March 2025. Total expenditure, excluding depreciation, was 1.02 Cr in March 2025, down from 1.31 Cr in March 2024. Operating profit (PBDIT) showed a loss of -0.29 Cr in March 2025, worsening from -0.13 Cr in March 2024. Profit before tax also reflected losses, with -0.29 Cr in March 2025 compared to -0.13 Cr in March 2024. The profit after tax mirrored this trend, resulting in -0.29 Cr in March 2025. The company's reserves have been negative, standing at -14.73 Cr in March 2025, indicating ongoing financial challenges. The book value per share adjusted to -4.73 in March 2025, reflecting a decline from -4.44 in March 2024. Cash flow activities have remained stagnant, with no cash inflow or outflow reported across the years.<BR><BR>Breakdown:<BR>Roselabs Finance's financial performance has shown a modest increase in net sales, reaching 0.71 Cr in March 2025, although it declined from the previous year's 1.14 Cr. The total operating income also decreased slightly to 0.71 Cr in March 2025. The company has maintained no raw material or finished goods purchases, with employee costs rising marginally to 0.06 Cr. Manufacturing expenses decreased significantly from 1.13 Cr in March 2024 to 0.70 Cr in March 2025, contributing to a total expenditure of 1.02 Cr in March 2025. Operating profit (PBDIT) reflected a loss of -0.29 Cr, worsening from -0.13 Cr in the prior year, while profit before tax and profit after tax both reported losses of -0.29 Cr. The company's reserves have remained negative, indicating financial strain, with a book value per share of -4.73 in March 2025. Overall, the cash flow situation has been stagnant, with no reported cash movements over the years.

Which are the latest news on Roselabs Finance?

Why is Roselabs Finance falling/rising?

As of 03-Dec, Roselabs Finance Ltd's stock price is at 23.08, reflecting a slight decline and a bearish trend, having fallen consecutively for two days and showing a 17.57% decrease over the past month. The stock underperforms compared to the Sensex and trades below key moving averages, indicating ongoing negative sentiment.

As of 03-Dec, Roselabs Finance Ltd's stock price is currently at 23.08, reflecting a slight decline of 0.01 (-0.04%). The stock has been experiencing a downward trend, having fallen consecutively for the last two days and showing a return of -1.62% over the past week. This decline is further highlighted by its performance over the last month, where the stock has decreased by 17.57%, contrasting sharply with the Sensex, which has gained 1.34% during the same period.<BR><BR>Additionally, Roselabs Finance is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Despite a notable increase in delivery volume, which rose by 179.57% against the 5-day average, the overall sentiment remains negative as the stock has underperformed significantly year-to-date, with a decline of 34.02% compared to the Sensex's gain of 8.92%. <BR><BR>In summary, the combination of consecutive price falls, underperformance relative to the benchmark, and trading below key moving averages contribute to the current decline in Roselabs Finance's stock price.

Is Roselabs Finance overvalued or undervalued?

As of December 3, 2025, Roselabs Finance is considered risky and overvalued, with a PE ratio of -79.59 and significant financial distress, underperforming its peers and the Sensex with a return of -35.89%.

As of 3 December 2025, the valuation grade for Roselabs Finance has moved from very attractive to risky, indicating a significant deterioration in its financial standing. The company is currently assessed as overvalued, with a PE ratio of -79.59, an EV to EBIT of -28.02, and a ROCE of -31.00%. These figures highlight severe financial distress, particularly the negative earnings and book value.<BR><BR>In comparison to its peers, Roselabs Finance's valuation metrics starkly contrast with those of Bajaj Finance, which has a PE ratio of 34.68, and Life Insurance, with a PE of 10.75. The negative ratios for Roselabs Finance suggest that it is not only underperforming relative to its competitors but also reflects a lack of profitability and growth potential. Additionally, the company's stock has underperformed the Sensex significantly over the past year, with a return of -35.89% compared to the Sensex's 5.27%.